Skip to main content
Michael Lowe, MD, General Surgery, Atlanta, GA

MichaelCharlesLoweMDMA

General Surgery Atlanta, GA

Melanoma, Surgical Oncology (Other than Breast)

Associate Professor of Surgery at Emory University

Dr. Lowe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lowe's full profile

Already have an account?

  • Office

    1365 Clifton Rd NE
    B-4003
    Atlanta, GA 30322
    Phone+1 404-778-3303
    Fax+1 404-778-4255

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2014 - 2016
  • Emory University School of Medicine
    Emory University School of MedicineResidency, Surgery, 2007 - 2014
  • Emory University School of Medicine
    Emory University School of MedicinePost-Doctoral Fellowship, 2010 - 2012
  • Georgetown University School of Medicine
    Georgetown University School of MedicineClass of 2007
  • Georgetown University
    Georgetown UniversityMA, Bioethics, 2004 - 2005
  • Saint Joseph's University
    Saint Joseph's UniversityBS, Biology, Magna Cum Laude, 1998 - 2002

Certifications & Licensure

  • GA State Medical License
    GA State Medical License 2011 - 2026
  • GA State Medical License
    GA State Medical License 2010 - 2024
  • NY State Medical License
    NY State Medical License 2014 - 2017
  • American Board of Surgery Surgery
  • American Board of Surgery Complex General Surgical Oncology

Awards, Honors, & Recognition

  • Alpha Omega Alpha 2006
  • Phi Beta Kappa 2002

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable metastatic melanoma. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Neoadjuvant Strategy Establishes Standard of Care for Resectable Stage III Melanoma
    Neoadjuvant Strategy Establishes Standard of Care for Resectable Stage III MelanomaJune 4th, 2024

Professional Memberships